Furuya Fumihiko, Hanover John A, Cheng Sheue-yann
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1780-5. doi: 10.1073/pnas.0510849103. Epub 2006 Jan 30.
Activation of the phosphatidylinositol 3-kinase (PI3K)-AKT/protein kinase B signaling pathway has been associated with multiple human cancers. Recently we showed that AKT is activated in both the thyroid and metastatic lesions of a mouse model of follicular thyroid carcinoma [thyroid hormone beta receptor (TRbeta)(PV/PV) mice]. This TRbeta(PV/PV) mouse harbors a knock-in mutant TRbeta gene (TRbetaPV mutant) that spontaneously develops thyroid cancer and distant metastasis similar to human follicular thyroid cancer. Here we show that in thyroid tumors, PV mutant bound significantly more to the PI3K-regulatory subunit p85alpha, resulting in a greater increase in the kinase activity than did TRbeta1 in wild-type mice. By GST pull-down assays, the ligand-binding domain of TR was identified as the interaction site with p85alpha. By confocal fluorescence microscopy, p85alpha was shown to colocalize with TRbeta1 or PV mainly in the nuclear compartment of cultured tumor cells from TRbeta(PV/PV) mice, but cytoplasmic p85alpha/PV or p85alpha/TRbeta1 complexes were also detectable. Further biochemical analysis revealed that the activation of the PI3K-AKT-mammalian target of the rapamycin-p70(S6K) pathway was observed in both the cytoplasmic and nuclear compartments, whereas the activation of the PI3K-integrin-linked kinase-matrix metalloproteinase 2 pathway was detected mainly in the extranuclear compartments. These results suggest that PV, via the activation of p85alpha, could act to affect PI3K downstream signaling in both the nuclear and extranuclear compartments, thereby contributing to thyroid carcinogenesis. Importantly, the present study unveils a mechanism by which a mutant TR acts to activate PI3K activity via protein-protein interactions.
磷脂酰肌醇3激酶(PI3K)-AKT/蛋白激酶B信号通路的激活与多种人类癌症相关。最近我们发现,在滤泡性甲状腺癌小鼠模型[甲状腺激素β受体(TRβ)(PV/PV)小鼠]的甲状腺及转移灶中,AKT均被激活。这种TRβ(PV/PV)小鼠携带一个敲入突变的TRβ基因(TRβPV突变体),可自发发生甲状腺癌并出现远处转移,类似于人类滤泡性甲状腺癌。在此我们发现,在甲状腺肿瘤中,PV突变体与PI3K调节亚基p85α的结合显著多于野生型小鼠中的TRβ1,导致激酶活性的增加幅度更大。通过谷胱甘肽S-转移酶(GST)下拉实验,确定TR的配体结合结构域为与p85α的相互作用位点。通过共聚焦荧光显微镜观察,发现p85α主要与TRβ1或PV在来自TRβ(PV/PV)小鼠的培养肿瘤细胞的核区室中共定位,但也可检测到胞质中的p85α/PV或p85α/TRβ1复合物。进一步的生化分析显示,PI3K-AKT-雷帕霉素哺乳动物靶标-p70(S6K)信号通路在胞质和核区室中均被激活,而PI3K-整合素连接激酶-基质金属蛋白酶2信号通路的激活主要在核外区室中被检测到。这些结果表明,PV通过激活p85α,可能在核内和核外区室中影响PI3K下游信号,从而促进甲状腺癌发生。重要的是,本研究揭示了一种突变型TR通过蛋白质-蛋白质相互作用激活PI3K活性的机制。